August 30, 2019
Shionogi said on August 29 that its anti-flu agent Xofluza (baloxavir marboxil) has been approved in Taiwan for the treatment of acute influenza type A/B in patients 12 years of age and older. The Osaka-based company, which originated the drug,...read more